# Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

> **NCT05250947** · PHASE1 · TERMINATED · sponsor: **Matthew Pingree** · enrollment: 4 (actual)

## Conditions studied

- Lumbar Spondylosis

## Interventions

- **DEVICE:** Angel® Concentrated Platelet Rich Plasma System
- **DRUG:** Platelet Rich Plasma

## Key facts

- **NCT ID:** NCT05250947
- **Lead sponsor:** Matthew Pingree
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-05
- **Primary completion:** 2024-05-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Projected cost to continue was not supported by the study budget and additional funds could not be obtained so the decision to close the study was made.
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250947, "Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05250947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*